You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀微升藥明康德(02359.HK)目標價至197元 評級「買入」
阿思達克 08-20 11:02
瑞銀發表報告稱,受惠投資獲利及營運槓桿,藥明康德(02359.HK)上半年業績較預期好,預期合同研發生產(CDMO)將繼續強勁,故將目標價由196元輕微調高至197元,相當於明年預測市盈率99倍,維持「買入」評級。 不過,瑞銀指,美國實驗室及臨床試驗業務仍未能盈利,受累全球疫情影響,以及部分項目延遲或失敗,美國實驗室業務收入錄得按年下跌。 由於需求擴張,公司指引今年資本開支預算86億元人民幣;該行料明年資本開支維持高位。該行上調其今年每股盈測10%以反映中績勝預期;但下調明後兩年每股盈測分別13%及8%,以反映股權激勵計劃下相關行政開支增加。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account